Oncology · Prostate CancerTrial Updateclinicalmid-term

Genentech's GDC-1261 Study Targets Advanced Prostate Cancer Safety and Activity

Importance7/ 10

ActionMonitor

View Company Intelligence

Explore aggregated signals, assets, and competitive context for organizations linked to this signal.

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 7/13/2026, 12:30:33 PM

Assessment confidence: 73% · The main uncertainty is whether clinical benefit translates into regulatory momentum and guideline influence.

Executive Thesis

The ongoing trial of GDC-1261 by Genentech is significant as it targets advanced prostate cancer, a critical area in oncology. Positive outcomes could enhance Genentech's competitive positioning and influence treatment options in a crowded market. Regulatory context from MHRA (MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer) supports the near-term read. Assessment grounded in 16 ranked evidence items (10 high-relevance).

Strategic Assessment

Portfolio teams should monitor the trial outcomes closely, as successful results could enhance Genentech's position in oncology. The strongest clinical anchor is A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer (ClinicalTrials.gov), sub-indication match (prostate cancer); entity match (gdc-1261). In prostate cancer, 3 regulatory and 1 competitive items passed relevance filtering for Roche.

Competitive Pressure

The most relevant competitive pressure comes from Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival (Humanexa Signals) — sub-indication match (prostate cancer); sponsor/company relevance (merck). This trial may position GDC-1261 as a potential treatment option in a competitive prostate cancer landscape, where efficacy and safety are critical.

Regulatory Outlook

Regulatory risk is concentrated around MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer (MHRA). Sponsor/company relevance (Roche); Patient population match (advanced). Relevant agencies in corpus: MHRA, FDA. The trial's outcomes will be crucial for determining the next steps in regulatory submissions, including potential approval pathways based on safety and efficacy data.

Key Risks

Elevated medium regulatory exposure for Roche could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

If GDC-1261 demonstrates safety and efficacy, it could capture market share in the advanced prostate cancer segment, impacting revenue potential for Genentech.
Upside for Roche may improve if A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice (ClinicalTrials.gov) delivers favorable follow-through.
Upside for Roche may improve if Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641) (ClinicalTrials.gov) delivers favorable follow-through.
Oncology · Prostate Cancer · Trial Update · If successful, this combination could enhance Merck's position in the prostate cancer treatment market, competing directly with existing therapies.
This listing includes accelerated approvals (AAs) for malignant hematology and oncology indications that have postmarketing requirement(s) for ongoing clinical trial(s) to verify clinical benefit.

What Would Change This Assessment

This becomes more urgent if Key milestones include the identification of recommended doses and regimen, as well as preliminary activity results.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

MHRA approves Retifanlimab (ZYNYZ) for the treatment of advanced Merkel cell skin cancer
MHRAmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Ongoing | Cancer Accelerated Approvals
FDAmedium relevance
Sponsor/company relevance (Roche); Regulatory pathway relevance (approval)
FDA document
View source
FDA Approves New Treatment That Uses Donor Immune Cells to Prevent Serious Complications in Blood Cancer Patients
FDAmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Activity of GDC-1261 in Participants With Advanced or Metastatic Prostate Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Entity match (gdc-1261)
FDA document
View source
A Study to Learn How Men With Advanced Prostate Cancer Respond to Treatment With Darolutamide and Hormone Therapy, With or Without Chemotherapy, in Real-world Medical Practice
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Merck)
FDA document
View source
A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitors (ARPIs) for Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer (de N
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
ClinicalTrials.govhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy
ClinicalTrials.govhigh relevance
Mechanism alignment (IO ); Sponsor/company relevance (AstraZeneca)
FDA document
View source

Pembrolizumab Plus Enzalutamide Trial in mCRPC Shows Promise for Overall Survival
Humanexa Signalshigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Merck)

Targeting the PI3K/AKT pathway in prostate cancer: the role of PTEN deficiency and biomarker-guided therapy.
PubMedhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
Gut microbial metabolism of Flutamide attenuates its therapeutic efficacy against prostate cancer.
PubMedhigh relevance
Sub-indication match (prostate cancer); Sponsor/company relevance (Roche)
FDA document
View source
Efficacy and safety of cabozantinib plus nivolumab in advanced non-clear cell renal cell carcinoma: a nationwide multicenter study.
PubMedmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Effectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Sponsor/company relevance (Roche); Patient population match (advanced)
FDA document
View source
Elevated ESR2 and BRCA1 gene expression in adenomyosis associated with endometrial cancer: a pilot study.
PubMedmedium relevance
Sponsor/company relevance (Roche)
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Roche
GDC-1261

Commercial impact

medium

If GDC-1261 demonstrates safety and efficacy, it could capture market share in the advanced prostate cancer segment, impacting revenue potential for Genentech.

Regulatory impact

medium

The trial's outcomes will be crucial for determining the next steps in regulatory submissions, including potential approval pathways based on safety and efficacy data.

What to watch

Key milestones include the identification of recommended doses and regimen, as well as preliminary activity results.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.